From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo .
DR1 Human Pre-designed siRNA Set A contains three designed siRNAs for DR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
J10-1 is a hapten. J10-1 promotes peptide exchange of all DR alleles (DR1, DR2, DR4 (DRB1*0401)) and promotes peptide binding to MHC II, which can be used in the study of immune regulation .
UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
Cyclobisdemethoxycurcumin is an antioxidant agent with IC50s of ~250 μM and 15-20 μM in DPPH radical scavenging assay and 2-DR oxidation assay, respectively .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Loxapine-d8 (hydrochloride) is the deuterium labeled Loxapine. Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent[1][2].
Fluphenazine-d8 (dihydrochloride) is the deuterium labeled Fluphenazine dihydrochloride. Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor; used to deliver Fluphenazine to biological systems in studies probing the effects and metabolic fates of this commonly used dopamine antagonist.
Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .
Antitubercular agent-29 (compound 6xa) is a potent agent resistant (DR) Mycobacterium tuberculosis (Mtb) inhibitor with MIC of 0.03 μg/mL against agent-susceptible (DS)-Mtb strains, MIC of 0.03-0.06 μg/mL against DR-Mtb strains, and favourable selectivity (SI>40) against Vero cells .
Octoclothepin maleate salt, an orally active neuroleptic agent, is a dual SR-2A and D2DR inhibitor. Octoclothepin maleate salt reveals an intensive central depressant action in a series of observational and instrumental procedures in rodents .
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR) .
Quercetin 3,4′-dimethyl ether (3,4′-Dimethylquercetin) is a dimethoxyflavone can be isolated from Combretum quadrangulare. Quercetin 3,4′-dimethyl ether overcomes TRAIL resistance by enhancing DR5 expression and has anti-tumor activity .
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) is an antagonist of interferon γ (IFN γ). IFN-γ Antagonist 1 inhibits IFN-γ induced HLR/DR antigen expression in Colon 205 cells with an IC50 value of approximately 35 μM. IFN-γ Antagonist 1 has potential applications in immune regulation .
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate is an antagonist of interferon γ (IFN γ). IFN-γ Antagonist 1 inhibits IFN-γ induced HLR/DR antigen expression in Colon 205 cells with an IC50 value of approximately 35 μM. IFN-γ Antagonist 1 has potential applications in immune regulation .
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP85-99 to HLA-DR2. J5 peptide alleviates PLP139-151/MBP85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
SKF-83566 hydrobromide is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT2 receptor (Ki=11 nM) . SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50 of 5.7 μM . SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta . SKF-83566 can be used for the research of parkinson’s disease and nicotine craving alleviation .
SKF-83566 is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT2 receptor (Ki=11 nM) . SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC50 of 5.7 μM . SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC1 and AC5 in the isolated rabbit thoracic aorta . SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation .
P53R3 is a potent p53 reactivator and restores sequence-specific DNA binding of p53 hot spot mutants, including p53 R175H, p53 R248W and p53 R273H. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1. P53R3 enhances the recruitment of wild-type p53 and p53 M237I to several target gene promoters. P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5 (DR5). P53R3 is used for cancer research .
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate is an antagonist of interferon γ (IFN γ). IFN-γ Antagonist 1 inhibits IFN-γ induced HLR/DR antigen expression in Colon 205 cells with an IC50 value of approximately 35 μM. IFN-γ Antagonist 1 has potential applications in immune regulation .
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide sequence. NY-ESO-1 (87-111) binds to multiple HLA-DR and HLA-DP4 molecules, and stimulates Th1-type and Th-2/Th0-type CD4 + T cells when presented in the context of HLA-DR and HLA-DP4 molecules .
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) is an antagonist of interferon γ (IFN γ). IFN-γ Antagonist 1 inhibits IFN-γ induced HLR/DR antigen expression in Colon 205 cells with an IC50 value of approximately 35 μM. IFN-γ Antagonist 1 has potential applications in immune regulation .
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP85-99 to HLA-DR2. J5 peptide alleviates PLP139-151/MBP85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM) .
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .
Cyclobisdemethoxycurcumin is an antioxidant agent with IC50s of ~250 μM and 15-20 μM in DPPH radical scavenging assay and 2-DR oxidation assay, respectively .
DR6/TNFRSF21 protein is the core of apoptosis and may activate NF-kappa-B and promote BAX-mediated apoptosis through cytochrome c release. In neuronal apoptosis, it responds to amyloid peptides in APP, which is critical for cell body death and axonal pruning. DR6/TNFRSF21 Protein, Rat (HEK293, Fc) is the recombinant rat-derived DR6/TNFRSF21 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of DR6/TNFRSF21 Protein, Rat (HEK293, Fc) is 349 a.a., with molecular weight of ~95-115 kDa.
DR6/TNFRSF21 protein is the core protein of apoptosis and can activate NF-kappa-B, BAX-mediated apoptosis and mitochondrial cytochrome c release. In neuronal apoptosis, it is critical for amyloid peptide-triggered cell body death and axonal pruning. DR6/TNFRSF21 Protein, Human (HEK293) is the recombinant human-derived DR6/TNFRSF21 protein, expressed by HEK293 , with tag free. The total length of DR6/TNFRSF21 Protein, Human (HEK293) is 350 a.a., with molecular weight of 55-60 kDa.
DR6/TNFRSF21 protein is the core protein of apoptosis and can activate NF-kappa-B, BAX-mediated apoptosis and mitochondrial cytochrome c release. In neuronal apoptosis, it is critical for amyloid peptide-triggered cell body death and axonal pruning. DR6/TNFRSF21 Protein, Human (HEK293, Fc) is the recombinant human-derived DR6/TNFRSF21 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of DR6/TNFRSF21 Protein, Human (HEK293, Fc) is 350 a.a., with molecular weight of 95-100 kDa.
Tnfrsf21 Protein, also known as death receptor 6 (DR6), CD358, or BM-018, is highly expressed in differentiating neurons as well as in the adult brain, and is upregulated in injured neurons. DR6 negatively regulates neuron, axon, and oligodendrocyte survival, hinders axondendrocyte and oligodendrocyte regeneration and its inhibition has a neuro-protective effect in nerve injury. It activates nuclear factor kappa-B (NFkB) and mitogen-activated protein kinase 8 (MAPK8, also called c-Jun N-terminal kinase 1), and induces cell apoptosis by associating with TNFRSF1A-associated via death domain (TRADD), which is known to mediate signal transduction of tumor necrosis factor receptors. DR6/TNFRSF21 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived DR6/TNFRSF21 protein, expressed by HEK293 , with C-His labeled tag. The total length of DR6/TNFRSF21 Protein, Cynomolgus (HEK293, His) is 309 a.a., with molecular weight of ~55-75 KDa.
The DR6/TNFRSF21 protein participates in multiple cellular processes and promotes apoptosis through NF-kappa-B activation, BAX-mediated pathways, and cytochrome c release. It is critical for neuronal apoptosis, particularly in response to APP-derived amyloid peptides, and is critical for normal cell body death and axonal pruning. DR6/TNFRSF21 Protein, Mouse (HEK293, Fc-His) is the recombinant mouse-derived DR6/TNFRSF21 protein, expressed by HEK293 , with C-hFc, C-6*His labeled tag. The total length of DR6/TNFRSF21 Protein, Mouse (HEK293, Fc-His) is 308 a.a., with molecular weight of 75-120 kDa.
DR6/TNFRSF21 protein is the core protein of apoptosis and can activate NF-kappa-B, BAX-mediated apoptosis and mitochondrial cytochrome c release. In neuronal apoptosis, it is critical for amyloid peptide-triggered cell body death and axonal pruning. DR6/TNFRSF21 Protein, Human (309a.a, HEK293, His) is the recombinant human-derived DR6/TNFRSF21 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of DR6/TNFRSF21 Protein, Human (309a.a, HEK293, His) is 309 a.a., with molecular weight of ~58 kDa.
The DR6/TNFRSF21 protein participates in multiple cellular processes and promotes apoptosis through NF-kappa-B activation, BAX-mediated pathways, and cytochrome c release. It is critical for neuronal apoptosis, particularly in response to APP-derived amyloid peptides, and is critical for normal cell body death and axonal pruning. DR6/TNFRSF21 Protein, Mouse (349a.a, HEK293, His) is the recombinant mouse-derived DR6/TNFRSF21 protein, expressed by HEK293 , with C-His labeled tag. The total length of DR6/TNFRSF21 Protein, Mouse (349a.a, HEK293, His) is 349 a.a., with molecular weight of 55-60 kDa.
The DR3/TNFRSF25 protein displays defects in conserved residues critical for propagation feature annotation. This defect in DR3/TNFRSF25 prevents the propagation of specific functional features associated with this protein. DR3/TNFRSF25 Protein, Mouse (HEK293, His) is the recombinant mouse-derived DR3/TNFRSF25 protein, expressed by HEK293 , with C-His labeled tag. The total length of DR3/TNFRSF25 Protein, Mouse (HEK293, His) is 166 a.a., with molecular weight of 35-48 kDa.
TRAIL R2/TNFRSF10B Protein, a receptor for TNFSF10/TRAIL, initiates apoptosis by recruiting caspase-8 via FADD. It forms the death-inducing signaling complex (DISC), activating caspases and mediating apoptosis. TRAIL R2/TNFRSF10B also activates NF-kappa-B and plays a crucial role in endoplasmic reticulum stress-induced apoptosis. In its monomeric state, it interacts with TRADD and RIPK1, and stimulation enhances interactions with BIRC2 and DDX3X. Notably, it interacts with HCMV protein UL141, highlighting its multifaceted role in apoptotic and signaling pathways. TRAIL R2/TNFRSF10B Protein, Human (HEK293, His-Avi) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (HEK293, His-Avi) is 127 a.a., with molecular weight of 20-25 kDa.
DR3/TNFRSF25 Protein, the receptor for TNFSF12/APO3L/TWEAK, interacts with adapter TRADD, activating NF-kappa-B and inducing apoptosis. It may crucially regulate lymphocyte homeostasis. Forming homodimers, it strongly interacts with TNFRSF1 and TRADD via death domains, initiating distinct apoptosis and NF-kappa-B signaling cascades. Interaction with BAG4 contributes to its multifaceted cellular response roles. DR3/TNFRSF25 Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived DR3/TNFRSF25 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of DR3/TNFRSF25 Protein, Human (Biotinylated, HEK293, Fc) is 175 a.a., with molecular weight of ~45.9 KDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His-Avi) is 127 a.a., with molecular weight of 20-25 kDa.
TRAIL R2/TNFRSF10B Protein, a receptor for TNFSF10/TRAIL, activates apoptosis through FADD-mediated recruitment of caspase-8, forming the death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, crucial for ER stress-induced apoptosis. In its monomeric form, it interacts with TRADD and RIPK1. Upon stimulation, enhanced interactions occur with BIRC2, DDX3X, and GSK3B, leading to DDX3X and BIRC2 cleavage. TRAIL R2/TNFRSF10B Protein, Mouse (128a.a, HEK293, His) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293, with C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (128a.a, HEK293, His) is 128 a.a., with molecular weight of 30-40 kDa.
DR3/TNFRSF25 Protein, the receptor for TNFSF12/APO3L/TWEAK, interacts with adapter TRADD, activating NF-kappa-B and inducing apoptosis. It may crucially regulate lymphocyte homeostasis. Forming homodimers, it strongly interacts with TNFRSF1 and TRADD via death domains, initiating distinct apoptosis and NF-kappa-B signaling cascades. Interaction with BAG4 contributes to its multifaceted cellular response roles. DR3/TNFRSF25 Protein, Human (177a.a, HEK293, Fc) is the recombinant human-derived DR3/TNFRSF25 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of DR3/TNFRSF25 Protein, Human (177a.a, HEK293, Fc) is 177 a.a., with molecular weight of 50-55 kDa.
DR6/TNFRSF21 Protein, central to apoptosis, activates NF-kappa-B, BAX-mediated apoptosis, and mitochondrial cytochrome c release. In neuronal apoptosis, it's pivotal for amyloid peptide-triggered cell body death and axonal pruning. It negatively regulates oligodendrocyte survival, maturation, and myelination. In T-cell signaling, it's crucial for differentiation, proliferation, and immune response, inhibiting T-cell cytokine release and Ig production. Additionally, it regulates pyroptosis by recruiting CASP8 upon ROS stimulation. Interactions include NGFR, CASP8, N-APP, and association with TRADD. DR6/TNFRSF21 Protein, Human (His-SUMO) is the recombinant human-derived DR6/TNFRSF21 protein, expressed by E. coli, with N-SUMO, N-6*His labeled tag. The total length of DR6/TNFRSF21 Protein, Human (His-SUMO) is 285 a.a., with molecular weight of 48 kDa.
TWEAK Protein refers to the cytokine tumor necrosis factor-like weak inducer of apoptosis, belongs to tumor necrosis factor (TNF) superfamily. TWEAK protein binds to FN14 and TNRFSF12/APO3, is a weak inducer of apoptosis. TWEAK does have pro-apoptotic activity for tumor cell, mediates NF-kappa-B activation, promotes angiogenesis and the proliferation of endothelial cells (ECs). TWEAK also increases IL-6 and IL-8 secretion, and could potentiate the pro-inflammatory activities of TNF and IL-1. Human TWEAK protein is a type II transmembrane protein (M1-H249) with a transmembrane domain (22-42 a.a.). TWEAK/TNFSF12 Protein, Human (CHO) is the extracellular part (R99-H249) of TWEAK protein, produced by CHO cells with tag free.
TWEAK Protein refers to the cytokine tumor necrosis factor-like weak inducer of apoptosis, belongs to tumor necrosis factor (TNF) superfamily. TWEAK protein binds to FN14 and TNRFSF12/APO3, is a weak inducer of apoptosis. TWEAK does have pro-apoptotic activity for tumor cell, mediates NF-kappa-B activation, promotes angiogenesis and the proliferation of endothelial cells (ECs). TWEAK also increases IL-6 and IL-8 secretion, and could potentiate the pro-inflammatory activities of TNF and IL-1. Mouse TWEAK protein is a type II transmembrane protein (M1-H249) with a transmembrane domain (25-45 a.a.). TWEAK/TNFSF12 Protein, Mouse (HEK293, Fc) is the extracellular part (R105-H249) of TWEAK protein, produced by HEK293 cells (R105-H249) with N-terminal hFc-tag.
TWEAK Protein refers to the cytokine tumor necrosis factor-like weak inducer of apoptosis, belongs to tumor necrosis factor (TNF) superfamily. TWEAK protein binds to FN14 and TNRFSF12/APO3, is a weak inducer of apoptosis. TWEAK does have pro-apoptotic activity for tumor cell, mediates NF-kappa-B activation, promotes angiogenesis and the proliferation of endothelial cells (ECs). TWEAK also increases IL-6 and IL-8 secretion, and could potentiate the pro-inflammatory activities of TNF and IL-1. Mouse TWEAK protein is a type II transmembrane protein (M1-H249) with a transmembrane domain (25-45 a.a.). TWEAK/TNFSF12 Protein, Mouse (HEK293, rFc) is the extracellular part (R105-H249) of TWEAK protein, produced by HEK293 cells (R105-H249) with N-terminal rFc-tag.
TWEAK Protein refers to the cytokine tumor necrosis factor-like weak inducer of apoptosis, belongs to tumor necrosis factor (TNF) superfamily. TWEAK protein binds to FN14 and TNRFSF12/APO3, is a weak inducer of apoptosis. TWEAK does have pro-apoptotic activity for tumor cell, mediates NF-kappa-B activation, promotes angiogenesis and the proliferation of endothelial cells (ECs). TWEAK also increases IL-6 and IL-8 secretion, and could potentiate the pro-inflammatory activities of TNF and IL-1. TWEAK protein is a type II transmembrane protein (M1-H249) with a transmembrane domain. TWEAK/TNFSF12 Protein, Rat (HEK293, Fc) is produced by HEK293 cells (R105-H249) with N-terminal rFc-tag.
TWEAK Protein refers to the cytokine tumor necrosis factor-like weak inducer of apoptosis, belongs to tumor necrosis factor (TNF) superfamily. TWEAK protein binds to FN14 and TNRFSF12/APO3, is a weak inducer of apoptosis. TWEAK does have pro-apoptotic activity for tumor cell, mediates NF-kappa-B activation, promotes angiogenesis and the proliferation of endothelial cells (ECs). TWEAK also increases IL-6 and IL-8 secretion, and could potentiate the pro-inflammatory activities of TNF and IL-1. Human TWEAK protein is a type II transmembrane protein (M1-H249) with a transmembrane domain (22-42 a.a.). Animal-Free TWEAK/TNFSF12 Protein, Human (His) is the extracellular part (K97-H249) of TWEAK protein, produced by E. coli with C-terminal His-tag.
TWEAK/TNFSF12 Protein binds to FN14 and potentially TNRFSF12/APO3, weakly inducing apoptosis in certain cells. It activates NF-kappa-B, enhances angiogenesis, and stimulates endothelial cell proliferation. Furthermore, TWEAK/TNFSF12 is implicated in inflammatory cytokine induction and promotes IL8 secretion. It forms a homotrimer and interacts with the angiogenic factor AGGF1/VG5Q. TWEAK/TNFSF12 Protein, Human (HEK293, hFc) is the recombinant human-derived TWEAK/TNFSF12 protein, expressed by HEK293, with C-hFc labeled tag. The total length of TWEAK/TNFSF12 Protein, Human (HEK293, hFc) is 207 a.a., with molecular weight of 50-60 kDa.
TWEAK Protein refers to the cytokine tumor necrosis factor-like weak inducer of apoptosis, belongs to tumor necrosis factor (TNF) superfamily. TWEAK protein binds to FN14 and TNRFSF12/APO3, is a weak inducer of apoptosis. TWEAK does have pro-apoptotic activity for tumor cell, mediates NF-kappa-B activation, promotes angiogenesis and the proliferation of endothelial cells (ECs). TWEAK also increases IL-6 and IL-8 secretion, and could potentiate the pro-inflammatory activities of TNF and IL-1. Human TWEAK protein is a type II transmembrane protein (M1-H249) with a transmembrane domain (22-42 a.a.). TWEAK/TNFSF12 Protein, Human/Cynomolgus (HEK293, Fc) is the extracellular part (S97-H249) of TWEAK protein, produced by HEK293 cells with N-terminal mFc-tag.
TWEAK Protein refers to the cytokine tumor necrosis factor-like weak inducer of apoptosis, belongs to tumor necrosis factor (TNF) superfamily. TWEAK protein binds to FN14 and TNRFSF12/APO3, is a weak inducer of apoptosis. TWEAK does have pro-apoptotic activity for tumor cell, mediates NF-kappa-B activation, promotes angiogenesis and the proliferation of endothelial cells (ECs). TWEAK also increases IL-6 and IL-8 secretion, and could potentiate the pro-inflammatory activities of TNF and IL-1. Mouse TWEAK protein is a type II transmembrane protein (M1-H249) with a transmembrane domain (25-45 a.a.). TWEAK/TNFSF12 Protein, Mouse (HEK293, rFc) is the extracellular part (R105-H249) of TWEAK protein, produced by HEK293 cells (R105-H249) with N-terminal rFc-tag.
TRAIL R1/TNFRSF10A protein is a receptor for TNFSF10/TRAIL, which recruits caspase-8 through FADD to initiate cell apoptosis and form a death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in the monomeric state. TRAIL R1/TNFRSF10A Protein, Human (HEK293, hFc) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TRAIL R1/TNFRSF10A Protein, Human (HEK293, hFc) is 216 a.a., with molecular weight of ~47 kDa.
TRAIL R1/TNFRSF10A Protein, a receptor for TNFSF10/TRAIL, initiates apoptosis by recruiting caspase-8 via FADD, forming the death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in its monomeric state. TRAIL R1/TNFRSF10A forms homooligomers and heterooligomers with TNFRSF10B, interacting with the TNFSF10 homotrimer. It also interacts with ARAP1 and ZDHHC3, highlighting its role in complex signaling networks. In the absence of stimulation, it interacts with BIRC2, DDX3X, and GSK3B, and stimulation enhances these interactions, accompanied by cleavage of DDX3X and BIRC2, emphasizing its multifaceted role in apoptotic and signaling pathways. TRAIL R1/TNFRSF10A Protein, Human (HEK293, His-Avi) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of TRAIL R1/TNFRSF10A Protein, Human (HEK293, His-Avi) is 206 a.a., with molecular weight of 25-30 kDa.
TRAIL R1/TNFRSF10A protein is a receptor for TNFSF10/TRAIL, which recruits caspase-8 through FADD to initiate cell apoptosis and form a death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in the monomeric state. TRAIL R1/TNFRSF10A Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of TRAIL R1/TNFRSF10A Protein, Human (Biotinylated, HEK293, His-Avi) is 206 a.a., with molecular weight of 25-30 kDa.
TRAIL R2/TNFRSF10B Protein serves as a receptor for the cytotoxic ligand TNFSF10/TRAIL. Upon ligand binding, the adapter molecule FADD recruits caspase-8 to the activated receptor, forming the death-inducing signaling complex (DISC). This activation leads to a cascade of caspases, mediating apoptosis. TRAIL R2/TNFRSF10B lacks conserved residue(s) crucial for feature annotation propagation. TRAIL R2/TNFRSF10B Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293, with C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Cynomolgus (HEK293, His) is 155 a.a., with molecular weight of 25-35 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (HEK293, hFc) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (HEK293, hFc) is 127 a.a., with molecular weight of ~41 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (Biotinylated, HEK293, His) is 127 a.a., with molecular weight of ~15.8 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc, C-His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, His-Fc) is 125 a.a., with molecular weight of 50-55 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, Avi-His) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, Avi-His) is 125 a.a., with molecular weight of 20-40 kDa.
TRAIL R1/TNFRSF10A protein is a receptor for TNFSF10/TRAIL, which recruits caspase-8 through FADD to initiate cell apoptosis and form a death-inducing signaling complex (DISC). It activates NF-kappa-B and interacts with TRADD and RIPK1 in the monomeric state. TRAIL R1/TNFRSF10A Protein, Human (216a.a, HEK293, His) is the recombinant human-derived TRAIL R1/TNFRSF10A protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TRAIL R1/TNFRSF10A Protein, Human (216a.a, HEK293, His) is 216 a.a., with molecular weight of 19-30 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK 293, hFc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK 293, hFc) is 125 a.a., with molecular weight of ~50 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by E. coli , with tag free. The total length of TRAIL R2/TNFRSF10B Protein, Human is 132 a.a., with molecular weight of ~14.8 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and recruits caspase-8 through FADD to initiate cell apoptosis. It forms the death-inducing signaling complex (DISC), activates caspases and mediates apoptosis. TRAIL R2/TNFRSF10B Protein, Human (127a.a, HEK293, His) is the recombinant human-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Human (127a.a, HEK293, His) is 127 a.a., with molecular weight of ~18.0 kDa.
CD21 Protein, a receptor for complement C3, Epstein-Barr virus, and HNRNPU, activates B lymphocytes and aids Epstein-Barr virus entry in microbial infection. Its engagement with these ligands highlights its vital role in immune responses and interactions, regulating B-cell activation and host defense against infections. CD21 Protein, Human (HEK293, His) is the recombinant human-derived CD21 protein, expressed by HEK293 , with C-His, C-10*His labeled tag. The total length of CD21 Protein, Human (HEK293, His) is 951 a.a., with molecular weight of 110-120 kDa.
CD21 protein, as a receptor for complement C3d and HNRNPU, plays a crucial role in B lymphocyte activation. It forms complexes with CD19, CR2/CD21, CD81 and IFITM1/CD225 and contributes to immune responses. CD21 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD21 protein, expressed by HEK293 , with C-His labeled tag. The total length of CD21 Protein, Mouse (HEK293, His) is 952 a.a., with molecular weight of 130-150 kDa.
TRAIL R2/TNFRSF10B protein is the receptor of TNFSF10/TRAIL and activates apoptosis through FADD-mediated recruitment of caspase-8 to form death-inducing signaling complex (DISC). It initiates caspase cascade-mediated apoptosis and promotes NF-kappa-B activation, which is critical for ER stress-induced apoptosis. TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived TRAIL R2/TNFRSF10B protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TRAIL R2/TNFRSF10B Protein, Mouse (HEK293, hFc) is 125 a.a., with molecular weight of 50-75 kDa.
Fluphenazine-d8 (dihydrochloride) is the deuterium labeled Fluphenazine dihydrochloride. Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor; used to deliver Fluphenazine to biological systems in studies probing the effects and metabolic fates of this commonly used dopamine antagonist.
Loxapine-d8 (hydrochloride) is the deuterium labeled Loxapine. Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent[1][2].
DR5 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 48 kDa, targeting to DR5. It can be used for WB,IP,IHC-P,FC assays with tag free, in the background of Human.
DRD2 Antibody is an unconjugated, approximately 51 kDa, rabbit-derived, anti-DRD2 polyclonal antibody. DRD2 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in rat, and predicted: human, mouse background without labeling.
